The use of rituximab in the treatment of rheumatoid arthritis (RA)-associated bronchiectasis (BR) helps stabilize or improve pulmonary symptoms, with a more favourable respiratory survival over a 5-year follow-up as compared with tumour necrosis factor inhibitors (TNFi), according to a retrospective study.
Women with primary Sjögren’s syndrome experience vaginal dryness, which contributes to sexual dysfunction and dyspareunia, as reported in a study. The dryness may be attributed to a peri-epithelial infiltration and decreased number of vascular smooth muscle cells in the vaginal wall.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
Treatment with denosumab in patients with osteoporosis and diabetes yields a substantial increase in bone mineral density (BMD) and a reduction in the risk of vertebral, but not nonvertebral, fractures, a study has found.
Postmenopausal women with vitamin D deficiency are at greater odds of having lumbar disc degeneration (LDD) and low back pain (LBP), with a serum vitamin D concentration of <10 ng/mL being a marker of severe LDD and LBP, as reported in a recent study.
A long-term course of once-weekly tocilizumab in patients with Takayasu arteritis appears to exert a steroid-sparing effect and yields improvements in well-being without raising new safety concerns, according to data from the Takayasu Arteritis Treated with Tocilizumab trial.
Rheumatoid arthritis (RA) patients who exhibit low rheumatoid factor (RF), as well as low disease activity, following treatment with certolizumab pegol (CZP) plus methotrexate (MTX) may be able to discontinue CZP without the increased risk of loss of remission, a recent study has shown.
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.